Safety and efficacy of phage therapy via the intravenous route

FEMS Microbiology Letters

Volumn 363, Issue 3, 2015, Pages

  Speck, Peter ^a   Smithyman, Anthony ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Bacteriophage therapy; Intravenous route; Staphylococcus aureus; Typhoid

Indexed keywords

CESIUM CHLORIDE; ENDOTOXIN;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ARTHRITIS; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BRONCHIECTASIS; CHRONIC BRONCHITIS; EUPHORIA; GOOD MANUFACTURING PRACTICE; HUMAN; LUNG ABSCESS; MASTITIS; MORTALITY RATE; NONHUMAN; OSTEOMYELITIS; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; RHINOSINUSITIS; RISK FACTOR; SEPSIS; SEPTICEMIA; SHIGELLA DYSENTERIAE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TYPHOID FEVER; ADVERSE DRUG REACTION; ADVERSE EFFECTS; BIOLOGICAL THERAPY; GROWTH, DEVELOPMENT AND AGING; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; TYPHOID FEVER;

EID: 84960145511     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1093/femsle/fnv242     Document Type: Article

References (55)

1. Abedon ST, Kuhl SJ, Blasdel BG et al. Phage treatment of human infections. Bacteriophage 2011;1:66-85.
2. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
3. Agarwal A, Vieira CA, Book BK et al. Rituximab, anti-CD20, inhibits a human in vivo primary and secondary antibody response to bacteriophage phi X174. Blood 2001;98:608A.
4. Arens JF, Lejeune FE, Webre DR. Maxillary sinusitis, a complication of nasotracheal intubation. Anesthesiology 1974;40: 415-6.
5. Bearden CM, Agarwal A, Book BK et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005;5:50-7.
6. Beckfrich A, Hauduroy P. The bacteriophage in the treatment of the typhoid fever. C R Seances Soc Biol Fil 1922;86:168-70.
7. Bernstein LJ, Ochs HD,Wedgwood RJ et al. Defective humoral immunity in pediatric acquired immune-deficiency syndrome. J Pediatr 1985;107:352-7.
8. ChanishviliN. Phage therapy against septic infections. In:ALiterature Review of the Practical Application of Bacteriophage Research (Bacteriology Research Development). New York: Nova Science Publishers, 2012, 165-88.
9. Collignon PJ,Wilkinson IJ, Gilbert GL et al. Health care-associated Staphylococcus aureus bloodstream infections: a clinical quality indicator for all hospitals. Med J Aust 2006;184:404-6.
10. Cunningham-Rundles C, Bodian C, Ochs HD et al. Long-term lowdose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol 2001;100:181-90.
11. d'Herelle F. An address on bacteriophagy and recovery from infectious diseases. Can Med Assoc J 1931a;24:619-28.
12. d'Herelle F. Bacteriophage as a treatment in acute medical and surgical infections. B New York Acad Med 1931b;7: 329-48.
13. Desranleau JM. The treatment of typhoid fever by the use of Vi antityphoid bacteriophages; a preliminary report. C J Public Health 1948;39:317-9.
14. Desranleau JM. Progress in the treatment of typhoid fever with Vi bacteriophages. C J Public Health 1949;40:473-8.
15. Drilling A, Morales S, Boase S et al. Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis. Int Forum Allergy Rhinol 2014;4: 176-86.
16. Dubos RJ, Straus JH, Pierce C. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with shigella dysenteriae. J Exp Med 1943;78: 161-8.
17. Duplantier JE, Seyama K, Day NK et al. Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin Immunol 2001;98:313-8.
18. Fass L, Ochs HD, Thomas ED et al. Studies of immunological reactivity following syngeneic or allogeneic marrow grafts in man. Transplantation 1973;16:630-40.
19. Finley RL, Collignon P, Larsson DGJ et al. The scourge of antibiotic resistance: the important role of the environment. Clin Infect Dis 2013;57:704-10.
20. Fogelman I, Davey V, Ochs HD et al. Evaluation of CD4(+) T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 2000;182: 435-41.
21. Geier MR, Trigg ME, Merril CR. Fate of bacteriophage-lambda in non-immune germfree mice. Nature 1973;246:221-3.
22. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). Eur Heart J 2009;30:2369-413.
23. Hauduroy P. The role of the bacteriophage in typhoid fever. C R Seances Soc Biol Fil 1925;93:100-1.
24. Hochstim CJ, Choi JY, Lowe D et al. Biofilm detection with hematoxylin-eosin staining. Arch Otolaryngol 2010;136: 453-6.
25. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA-J Am Med Assoc 2007;298:1763-71.
26. Knouf EG,Ward WE, Reichle PA et al. Treatment of typhoid fever with type specific bacteriophage - preliminary report. JAMA-J Am Med Assoc 1946;132:134-8.
27. Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 2010;11:69-86.
28. Lopez V, Ochs HD, Thuline HC et al. Defective antibody response to bacteriophage Phi-X-174 in Down syndrome. J Pediatr 1975;86:207-11.
29. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
30. MacNeal WJ. Specific Therapeutic Shock -the Hugh Young Reaction. Arch Surg 1941;43:579-82.
31. MacNeal WJ, Frisbee FC. Bacteriophage service to patients with staphylococcus septicemia. Am J Med Sci 1936a;191:170-8.
32. MacNeal WJ, Frisbee FC. One hundred patients with staphylococcus septicemia receiving bacteriophage service. Am J Med Sci 1936b;191:179-95.
33. Matsuzaki S, Rashel M, Uchiyama J et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 2005;11:211-9.
34. Mejer N, Westh H, Schonheyder HC et al. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis 2012;12:260.
35. Merril CR, Biswas B, Carlton R et al. Long-circulating bacteriophage as antibacterial agents. P Natl Acad Sci USA1996;93:3188-92.
36. Montclos H. Les bacteriophages therapeutique:del'emprirism ala biologie moleculaire. Pyrexie 2002;6:77-80.
37. O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 2009;33:801-19.
38. Ochs HD, Buckley RH, Kobayashi RH et al. Antibody responses to bacteriophage Phi-X174 in patients with adenosinedeaminase deficiency. Blood 1992;80:1163-71.
39. Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage PHI-X-174 in immunodeficiency diseases. J Clin Invest 1971;50:2559-68.
40. Ochs HD, Slichter SJ, Harker LA et al. Wiskott-Aldrich syndrome -studies of lymphocytes, granulocytes and platelets. Blood 1980;55:243-52.
41. Pyun KH, Ochs HD, Wedgwood RJ et al. Human antibody responses to bacteriophage PHI-X 174 -sequential induction of IgM and IgG subclass antibody. Clin Immunol Immunop 1989;51:252-63.
42. Rose T, Verbeken G, Vos DD et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 2014;4:66-73.
43. Rubinstein A, Mizrachi Y, Bernstein L et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage Phi X174 in asymptomatic HIV-1 infected patients. AIDS 2000;14: F55-62.
44. Sauve L. Le bactériophage in chirurgie. La Medicine 1936;17:49-54.
45. Seyama K, Nonoyama S, Gangsaas I et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood 1998;92:2421-34.
46. Shearer WT, Lugg DJ, Rosenblatt HM et al. Antibody responses to bacteriophage phi X-174 in human subjects exposed to the Antarctic winter-over model of spaceflight. J Allergy Clin Immunol 2001;107:160-4.
47. Smith J. The bacteriophage in the treatment of typhoid fever. Br Med J 1924;1924:47-9.
48. Speck P. Antibiotics: avert an impending crisis. Nature 2013;496:169.
49. Stummeyer K, Schwarzer D, Claus H et al. Evolution of bacteriophages infecting encapsulated bacteria: lessons from Escherichia coli K1-specific phages. Mol Microbiol 2006;60: 1123-35.
50. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Ch 2001;45:649-59.
51. Turnidge JD, Kotsanas D, MunckhofWet al. Staphylococcus aureus bacteraemia: a major cause ofmortality in Australia andNew Zealand. Med J Aust 2009;191:368-73.
52. Uhr JW, Lewis EW, Dancis J et al. Antibody response to bacteriophage phix 174 in newborn premature infants. J Clin Invest 1962;41:1509-13.
53. Vieu J. Int ér et des bactériophages dans le traitement de staphylococcies. Vie Med 1961;42:823-9.
54. Ward WE. Therapeutic use of specific typhoid bacteriophage. J Bacteriol 1946;51:58-9.
55. Witherspoon RP, Kopecky K, Storb RF et al. Immunological recovery in 48 patients following syngeneic marrow transplantation for hematological malignancy. Transplantation 1982;33:143-9.